Showing posts with label efflux pumps. Show all posts
Showing posts with label efflux pumps. Show all posts

Tuesday, 12 March 2024

Determine the Efflux Pump Mediated Resistance Mechanism of Acinetobacter baumannii and the Effect of (+) Usnic Acid as an Efflux Pump Inhibitor with Tigecycline | Chapter 10 | Advanced Concepts in Pharmaceutical Research Vol. 6

This chapter explores the efflux pump mediated resistance mechanism of Acinetobacter baumannii and the effect of (+) usnic acid as an Efflux pump inhibitor with tigecycline. Among the multi-drug resistant strains, Acinetobacter baumannii is a paramount pathogen in clinical terms, particularly in hospital-acquired infections. Overall, this bacterium is the most associated with nosocomial infections, particularly in intensive care units (ICUs). The most important aspect of the infection with A. baumannii strains is their resistance to entirely known antibiotics, suggesting the need for urgent action by the global health care community. MDRAb isolates (n = 100) (preserved at-70°C in trypticase-soy broth supplemented with 30% glycerol) collected between 2017 to 2019 from two different states in India (Andhra Pradesh & Telangana). For detection of efflux pump activity of tigecycline resistant Acinetobacter baumannii isolates, micro broth dilution method and real-time quantitative reverse transcription-polymerase chain reaction methods were used. (+) usnic acid was added to tigecycline and tested by checkerboard method to evaluate the efficacy as an efflux pump inhibitor.  In this study, we demonstrated the EPI activity of UA by using the EtBr agar cart wheel method and by reducing adeB gene expression using qRT-PCR, which resulted in a decrease in TGC resistance in A.baumannii. qRT-PCR analysis was done to show the down-regulation of the efflux pump in the isolates. Out of 42 tigecycline-resistant Acinetobacter baumannii isolates, 19 showed active efflux pump activity. All the 19 strains expressed adeB gene. (+) Usnic acid as adjuvant showed better efficacy in lowering the minimum inhibitory concentration when compared to conventional efflux pump inhibitor carbonyl cyanide phenylhydrazone. Plant derived compounds can act as an adjuvant to antibiotics, to increase the susceptibility to treat infectious diseases.


Author(s) Details:

B. Nagaraju,
Department of Pharmacology, Government Medical College and Hospital, Mahabubnagar, Telangana, 509001, India.

K. Fathimunnisa,
Department of Microbiology, Government Medical College and Hospital, Mahabubnagar, Telangana, 509001, India.

Please see the link here: https://stm.bookpi.org/ACPR-V6/article/view/13470


Tuesday, 19 October 2021

A Review on Resistance Mechanisms in Bacterial Biofilm Formations | Chapter 2 | Recent Developments in Medicine and Medical Research Vol. 3

 The goal of this review is to present the mechanisms that lead to antimicrobial treatment resistance in bacterial biofilms. Biofilm-forming bacteria are the source of chronic and recurrent illnesses. Joint prosthesis, intravenous catheters and stents, endotracheal tubes, and cardiovascular devices are also susceptible. The issue is massive since it leads to higher hospitalisation bills, frequent operations, and longer antibiotic use. Bacterial biofilms have different resistance mechanisms than planktonic cells. The following are some of them: Glycocalyx and extracellular polymeric substances (EPS), enzyme-mediated antibiotic resistance, cell heterogeneity in metabolism and growth rate, persister cells, genetic adaptation and mutations, efflux pumps, adverse environmental conditions, outer membrane structure, bacteriophages, interactions between different types of bacteria in polymicrobial biofilms The type of microorganism determines whether mechanism or combination of processes is used. As a result, a better understanding of their function will aid in discovering ways to combat the dangerous illnesses produced by biofilms.

  Author (S) Details Nikiforos Rodis

Medical School, Democritus University of Thrace, Greece.

Vasiliki Kalouda Tsapadikou

Medical School, Democritus University of Thrace, Greece.

Charalampos Potsios

Department of Internal Medicine, University General Hospital of Patras, Greece.

Panagiota Xaplanteri

Department of Microbiology, University General Hospital of Patras, Greece.